Venus Medtech focuses on the R&D of transvascular intervention device
Total raised: $37M
Investors 4
| Date | Name | Website |
| - | Qiming Ven... | qimingvent... |
| - | New Age Ve... | newagevent... |
| - | Qiming Ven... | qimingvc.c... |
| - | Cowin Capi... | cowincapit... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 28.03.2016 | - | $37M | Goldman Sa... |
Mentions in press and media 16
| Date | Title | Description |
| 26.05.2026 | Venus Medtech Hosts Inaugural Global Partner Summit in Paris | Company highlights international growth strategy, expanding structural heart portfolio, and commercialization priorities PARIS, May 26, 2026 /PRNewswire/ -- Venus Medtech convened its inaugural Global Partner Summit in Paris under the theme... |
| 25.10.2025 | Cardiovalve Completes TARGET Study Enrollment for CE Registration Study for Tricuspid Valve Replacement | The Company Advances Toward European CE Mark Submission with 150 Patients Enrolled; On Track for 2027 Commercial Launch HANGZHOU, China, Oct. 25, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as the &q... |
| 05.08.2025 | Court Sides with Cardiovalve in Edwards patent spat | HANGZHOU, China, Aug. 5, 2025 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. ("Venus Medtech", Stock Code: 02500.HK) recently announced a decisive legal victory for its wholly-owned subsidiary Cardiovalve Ltd. ("Cardiovalve&qu... |
| 22.04.2025 | Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations | HONG KONG, April 22, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced fin... |
| 08.09.2024 | Venus Medtech's Venus-Vitae: A New Dawn in Heart Valve Technology | In the world of medical innovation, every breakthrough can feel like a new dawn. Recently, Venus Medtech (Hangzhou) Inc. stepped into the spotlight with its next-generation transcatheter aortic valve replacement (TAVR) system, Venus-Vitae. ... |
| 05.09.2024 | Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study | HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house d... |
| 05.09.2024 | Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study | HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house d... |
| 14.06.2024 | Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S. | HANGZHOU, China, June 14, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that its in-house developed innovative tran... |
| 05.02.2024 | Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval | HANGZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that, VenusP-Valve, the company's in-house d... |
| 18.05.2018 | Venus Medtech Receives Equity Investment from DCP Capital | Venus Medtech, a Hangzhou, China-based heart valve technology developer, received an investment from DCP Capital. The amount of the deal was not disclosed. The company intends to use the funds to invest in R&D, production, and sales net... |
Show more